bio med and cml treatment

À propos de cette activité

Créé par

paankhuri bhatia

United Kingdom

Téléchargez la version pour jouer sur papier

Top 10 résultats

Il n'y a toujours pas de résultats pour ce jeu. Soyez le premier à apparaître dans le classement! Connectez-vous pour vous identifier.

Créez votre propre jeu gratuite à partir de notre créateur de jeu

Affrontez vos amis pour voir qui obtient le meilleur score dans ce jeu

Créer un défi


Compléter bio med and cml treatmentVersion en ligne bio med and cml treatment par paankhuri bhatia 1 Chronic myeloid leukaemia ( CML ) is a myeloproliferative disorder caused by the , which results from formation of the - fusion gene . This gene encodes active , which causes uncontrolled proliferation of cells . The main treatment for CML is biological therapy in the form of ( TKIs ) . The first - line treatment is , a TKI that works by competitively inhibiting the - of the BCR - ABL tyrosine kinase , preventing of downstream signalling and abnormal cell growth . Imatinib is indicated as first - line therapy in , but it may be contraindicated or poorly tolerated in patients with significant , , or due to adverse effects such as or symptoms . In patients who develop or intolerance to Imatinib , second - generation TKIs such as Dasatinib and Nilotinib may be used . Dasatinib is a more TKI that inhibits BCR - ABL as well as SRC family kinases but it is contraindicated in patients at risk of or . Nilotinib is another second - generation TKI that selectively inhibits BCR - ABL tyrosine kinase and may be used as an alternative first - line agent or in Imatinib resistance , although it is contraindicated in patients with or significant disease . Bosutinib is an additional second - generation TKI used in later - line therapy for patients to multiple TKIs , and its use may be limited by and side effects . Ponatinib is a third - generation TKI specifically effective against the T315I mutation of BCR - ABL , which confers resistance to other TKIs , and is indicated in , but it is contraindicated in patients with high risk due to increased risk of . In situations where TKIs are unsuitable , such as , Interferon - ? may be used as a biological therapy , as it works by modulating the immune response and inhibiting myeloid proliferation , although it is less and associated with - like side effects and symptoms . 2 jehbfhksbfks aeifb aifb aibf bjasfkjsfbjksdbf sbfjlsbfls iosfbjslf isbfsbf . s f 3 ekjfbksd sdubfkjsbf ioshfjsbf soiufgsjbfsalfnalsf . . svfjdskbfljsf oiashbfoisbfas oisfboaisfb asjlfaef .

Compléter

bio med and cml treatmentVersion en ligne

bio med and cml treatment

Chronic myeloid leukaemia ( CML ) is a myeloproliferative disorder caused by the , which results from formation of the - fusion gene . This gene encodes active , which causes uncontrolled proliferation of cells . The main treatment for CML is biological therapy in the form of ( TKIs ) . The first - line treatment is , a TKI that works by competitively inhibiting the - of the BCR - ABL tyrosine kinase , preventing of downstream signalling and abnormal cell growth . Imatinib is indicated as first - line therapy in , but it may be contraindicated or poorly tolerated in patients with significant , , or due to adverse effects such as or symptoms . In patients who develop or intolerance to Imatinib , second - generation TKIs such as Dasatinib and Nilotinib may be used . Dasatinib is a more TKI that inhibits BCR - ABL as well as SRC family kinases but it is contraindicated in patients at risk of or . Nilotinib is another second - generation TKI that selectively inhibits BCR - ABL tyrosine kinase and may be used as an alternative first - line agent or in Imatinib resistance , although it is contraindicated in patients with or significant disease . Bosutinib is an additional second - generation TKI used in later - line therapy for patients to multiple TKIs , and its use may be limited by and side effects . Ponatinib is a third - generation TKI specifically effective against the T315I mutation of BCR - ABL , which confers resistance to other TKIs , and is indicated in , but it is contraindicated in patients with high risk due to increased risk of . In situations where TKIs are unsuitable , such as , Interferon - ? may be used as a biological therapy , as it works by modulating the immune response and inhibiting myeloid proliferation , although it is less and associated with - like side effects and symptoms .

jehbfhksbfks aeifb aifb aibf bjasfkjsfbjksdbf sbfjlsbfls iosfbjslf isbfsbf . s f

ekjfbksd sdubfkjsbf ioshfjsbf soiufgsjbfsalfnalsf . . svfjdskbfljsf oiashbfoisbfas oisfboaisfb asjlfaef .

Vous pouvez intégrer le jeu dans un LMS compatible avec LTI 1.1 ou LTI 1.3 comme Canvas, Moodle ou Blackboard. Les scores seront ainsi automatiquement enregistrés dans le carnet de notes de la plateforme.

bio med and cml treatment

Compléter

À propos de cette activité

Créé par

Téléchargez la version pour jouer sur papier

Top Jeux

Compléter

COMPLETE THE LYRICS OF SONG

Compléter

FFA Creed Paragraph 3

Compléter

FFA Creed Paragraph #2

Compléter

The Preamble

Compléter

Anatomy quiz

Compléter

bio med and cml treatmentVersion en ligne

par paankhuri bhatia

		%
	Anonyme	%
		%
		%